Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics, for a total value of $825M USD.
The portfolio includes over-the-counter and prescription pharmaceutical products sold in Br...
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics, for a total value of $825M USD.
The portfolio includes over-the-counter and prescription pharmaceutical products sold in Br...
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics, for a total value of $825M USD.
The portfolio includes over-the-counter and prescription pharmaceutical products sold in Br...
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics, for a total value of $825M USD.
The portfolio includes over-the-counter and prescription pharmaceutical products sold in Br...
월튼 베스트팔렌 디벨롭먼트, 선순위 부채 전액 상환
월튼 베스트팔렌 디벨롭먼트 코퍼레이션(Walton Westphalia Development Corporation, 이하 ‘회사’)이 선순위 부채를 전액 상환했다고 발표했다.
올해 초 약 1630만달러였던 잔액이 2020년 1월 1A 단계 매각에 따른 수익금과 보유 현금을 결합해 모두 상환됐다.
기존의 선순위 부채 전액 상환으로 제2대출기관이었던 WWMN, LLC가 제1기관으로 이동했다.
에드워드 R 플레밍(Edward R. Fleming) 월...
월튼 베스트팔렌 디벨롭먼트, 선순위 부채 전액 상환
월튼 베스트팔렌 디벨롭먼트 코퍼레이션(Walton Westphalia Development Corporation, 이하 ‘회사’)이 선순위 부채를 전액 상환했다고 발표했다.
올해 초 약 1630만달러였던 잔액이 2020년 1월 1A 단계 매각에 따른 수익금과 보유 현금을 결합해 모두 상환됐다.
기존의 선순위 부채 전액 상환으로 제2대출기관이었던 WWMN, LLC가 제1기관으로 이동했다.
에드워드 R 플레밍(Edward R. Fleming) 월...